Philipp Ivanyi
YOU?
Author Swipe
View article: Real‐world efficacy and toxicity of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma according to <scp>IMDC</scp> risk criteria—A multi‐center retrospective analysis on behalf of the <scp>GUARDIANS</scp> group
Real‐world efficacy and toxicity of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma according to <span>IMDC</span> risk criteria—A multi‐center retrospective analysis on behalf of the <span>GUARDIANS</span> group Open
Ipilimumab and nivolumab are recommended as first‐line therapy for patients with metastatic or advanced renal cell carcinoma (aRCC) and International Metastatic RCC Database Consortium (IMDC) intermediate or poor risk. We retrospectively e…
View article: A Podcast Discussion on Medical Treatment in R/M-SCCHN in the Year 2025—Standard and Considerations for an Individualized Treatment
A Podcast Discussion on Medical Treatment in R/M-SCCHN in the Year 2025—Standard and Considerations for an Individualized Treatment Open
Recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) remains a disease with limited treatment options. Once salvage surgery or radiotherapy is no longer feasible, systemic medical therapy becomes the mainsta…
View article: Spatial atlasing of N-glycosylation in healthy control and clear cell renal cell carcinoma tissues linked with immune checkpoint inhibition response by MALDI mass spectrometry imaging
Spatial atlasing of N-glycosylation in healthy control and clear cell renal cell carcinoma tissues linked with immune checkpoint inhibition response by MALDI mass spectrometry imaging Open
This study represents an expanded spatial characterization of the normal renal N-glycome. Additionally, the N-glycomes of ccRCC tissues were compared relative to normal tissues, and in context of response to ICI. Candidate glycan-based bio…
View article: Supplementary Table S4 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)
Supplementary Table S4 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial) Open
Cell line Screen
View article: Supplementary Table S1 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)
Supplementary Table S1 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial) Open
Representativeness of Study participants
View article: Supplementary Figure S3 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)
Supplementary Figure S3 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial) Open
Structural Analyses of sunitinib, regorafenib and ripretinib in T670I-mutant KIT
View article: Supplementary Table S2 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)
Supplementary Table S2 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial) Open
ddPCR primer and probe sequences
View article: Supplementary Table S3 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)
Supplementary Table S3 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial) Open
Efficacy Assessment: CBR, best response
View article: Supplementary Figure S2 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)
Supplementary Figure S2 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial) Open
PFS by primary mutation
View article: Data from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)
Data from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial) Open
Purpose:Imatinib resistance is conferred by secondary mutations within the ATP-binding pocket or the activation loop of KIT in gastrointestinal stromal tumors (GIST). Ponatinib is active against KIT secondary activation loop and the…
View article: Supplementary Figure S1 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)
Supplementary Figure S1 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial) Open
CONSORT Diagram
View article: Guiding first-line treatment decisions in advanced urothelial carcinoma: a global survey
Guiding first-line treatment decisions in advanced urothelial carcinoma: a global survey Open
Background Enfortumab vedotin combined with pembrolizumab (EV-P) has become the new standard first-line therapy for patients with advanced urothelial carcinoma (aUC), based on its superior efficacy over platinum-based chemotherapy. As this…
View article: Low triglyceride levels are associated with increased risk of immune-related adverse events in patients receiving immune checkpoint inhibitors
Low triglyceride levels are associated with increased risk of immune-related adverse events in patients receiving immune checkpoint inhibitors Open
Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy by enhancing anti-tumor immune responses, yet their use can lead to immune-related adverse events (irAE), including neurological complications. Despite their clinical re…
View article: Impact of local therapy in metastatic renal cell carcinoma during medical treatment in a retrospective analysis
Impact of local therapy in metastatic renal cell carcinoma during medical treatment in a retrospective analysis Open
View article: Real-world Evidence from a Retrospective Multicentre Analysis on First-line Therapy for Metastatic Papillary Renal Cell Carcinoma. A GUARDIANS Project
Real-world Evidence from a Retrospective Multicentre Analysis on First-line Therapy for Metastatic Papillary Renal Cell Carcinoma. A GUARDIANS Project Open
In this report, we looked at the outcome of first-line treatment of patients with metastatic papillary renal cell cancer (pRCC). Tyrosine kinase inhibitor (TKI)-based therapies are applied frequently in pRCC. Our data support the use of im…
View article: Supplementary Data 1 from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Supplementary Data 1 from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Open
Supplementary material
View article: Data from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Data from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Open
Purpose:Treatment options for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) after failure of immune checkpoint inhibitor treatment and platinum-based chemotherapy are limited. Preliminary data suggested that mona…
View article: Impact of adding carboplatin to docetaxel chemotherapy on testosterone levels and treatment outcomes in metastatic docetaxel-resistant prostate cancer
Impact of adding carboplatin to docetaxel chemotherapy on testosterone levels and treatment outcomes in metastatic docetaxel-resistant prostate cancer Open
View article: Complement activation profiles in patients with immune checkpoint inhibitor-associated neuromuscular immune-related adverse events
Complement activation profiles in patients with immune checkpoint inhibitor-associated neuromuscular immune-related adverse events Open
Background Immune-related neuropathy (irNeuropathy) and myositis (irMyositis) are the most common neurologic adverse events (irAE-n) associated with immune checkpoint inhibitors. Although case reports suggest benefits of complement inhibit…
View article: Chromophobe renal cell carcinoma – a rare kidney cancer with limited therapy options: a narrative review
Chromophobe renal cell carcinoma – a rare kidney cancer with limited therapy options: a narrative review Open
Chromophobe renal cell carcinoma (chRCC) is a rare subtype of renal cell carcinoma (RCC) and is the most common form of non-clear cell renal cell carcinoma in young women. Compared to clear cell renal cell carcinoma (ccRCC), chRCC usually …
View article: Cost-effectiveness of cetuximab-containing regimens for squamous cell carcinoma of the head and neck in Italy
Cost-effectiveness of cetuximab-containing regimens for squamous cell carcinoma of the head and neck in Italy Open
CCRs are likely to represent a comparable or more effective treatment option compared to pembrolizumab ± chemotherapy. Model results consistently demonstrated that CCRs are a cost-effective treatment strategy. CCRs remain a relevant treatm…
View article: INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Open
Purpose: Treatment options for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) after failure of immune checkpoint inhibitor treatment and platinum-based chemotherapy are limited. Preliminary data suggested that mon…
View article: Correction: The sarcoma ring trial: a case-based analysis of inter-center agreement across 21 German-speaking sarcoma centers
Correction: The sarcoma ring trial: a case-based analysis of inter-center agreement across 21 German-speaking sarcoma centers Open
View article: Effectiveness, toxicity and treatment adjustments of lenvatinib plus pembrolizumab in advanced renal cell carcinoma: a multicenter real-world analysis
Effectiveness, toxicity and treatment adjustments of lenvatinib plus pembrolizumab in advanced renal cell carcinoma: a multicenter real-world analysis Open
View article: Quality of Life of Cancer Patients in Routine Clinical Care Using the Example of Checkpoint Inhibition Therapy: A Delphi Consensus
Quality of Life of Cancer Patients in Routine Clinical Care Using the Example of Checkpoint Inhibition Therapy: A Delphi Consensus Open
Introduction: The introduction of immune checkpoint inhibitors (CPIs) in oncology has improved the long-term perspectives of many patients and is bringing the quality of life (QoL) into focus as a treatment-relevant variable. In clinical r…
View article: Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial
Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial Open
View article: Treatment decision-making factors and sequencing in recurrent and/or metastatic squamous cell carcinoma of the head and neck
Treatment decision-making factors and sequencing in recurrent and/or metastatic squamous cell carcinoma of the head and neck Open
Treatment options for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) have evolved over the past decade and have helped improve survival outcomes for patients. Most national and regional g…
View article: Characterization of Hospital Admissions During Immune Checkpoint Inhibitor Therapy: Insights From the <scp>ICOG</scp> Study
Characterization of Hospital Admissions During Immune Checkpoint Inhibitor Therapy: Insights From the <span>ICOG</span> Study Open
Introduction Immune checkpoint inhibitors (ICI) have improved the therapeutic arsenal in outpatient oncology care; however, data on necessity of hospitalizations associated with immune‐related adverse events (irAEs) are scarce. Here, we ch…
View article: The sarcoma ring trial: a case-based analysis of inter-center agreement across 21 German-speaking sarcoma centers
The sarcoma ring trial: a case-based analysis of inter-center agreement across 21 German-speaking sarcoma centers Open
View article: Single-Session Surgical Intervention with Resection of a Primary Cranial Osteosarcoma and Cranioplasty using a 3D-Printed Craniotomy Template and Cranioplasty Molds
Single-Session Surgical Intervention with Resection of a Primary Cranial Osteosarcoma and Cranioplasty using a 3D-Printed Craniotomy Template and Cranioplasty Molds Open
Although osteosarcomas are the most frequent primary malignant bone tumors, the primary cranial manifestation of this condition is very rare with only a limited number of cases presented in the literature. We present the case of a 20-year-…